美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Invesco Nasdaq Biotechnology ETF

34.82

+0.34801.01%

盤後：34.40-0.4200-1.21%17:31 EDT

成交量：1.41萬

成交額：48.93萬

市值：9,679.96萬

市盈率：- -

高：34.92

開：34.52

低：34.42

收：34.47

52周最高：36.84

52周最低：23.42

股本：278.00萬

流通股本：278.00萬

量比：0.80

換手率：0.51%

股息：0.26

股息率：0.74%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

製藥巨頭諾華股價大跌近10%，遭遇三項藥物臨床試驗受挫

环球市场播报

安進股價盤前下跌5.4%；競爭對手諾華的膽固醇藥物後期臨床試驗失敗。

邁普醫學(301033.SZ)：「可吸收止血流體明膠」進入臨床試驗階段

邁普醫學：可吸收止血流體明膠作為第三類醫療器械進入臨床試驗

創新藥概念午後拉升，亞太藥業直線漲停，百普塞斯升逾10%，萬邦醫藥、皓元醫藥升逾6%。

諾華DM1藥物III期臨床試驗未達到主要終點

酶的戰爭：一場或將重塑全球創新藥競爭格局的「皮下革命」

富國銀行上調安進目標價至435美元

上半年創新藥冰火兩重天：百濟神州一款藥賣了超160億元，六成藥企還在求生

每日经济新闻

石藥集團(01093)：SYH2085片用於治療成人單純性流感的II期臨床試驗在中國正式啓動

石藥集團：SYH2085片II期臨床試驗在中國正式啓動

繼諾華之後，諾和諾德(NVO.US)終止兩項心血管臨床試驗

恒瑞醫藥(01276)：SHR-1179注射液獲得藥物臨床試驗批准通知書

榮昌生物：關於參加科創板2026年半年度創新藥行業集體業績説明會的公告

证券日报网

諾和諾德再次暫停了其實驗性心臟病藥物的兩項臨床試驗，進一步打擊了該藥的發展前景。

艾迪藥業：關於參加科創板2026年半年度創新藥行業集體業績説明會的公告

证券日报网

恒瑞醫藥(600276.SH)子公司HRS-1597片獲批開展臨床試驗

智飛生物(300122.SZ)：重組輪狀病毒亞單位疫苗(大腸桿菌)獲得臨床試驗批准

恒瑞醫藥：子公司HRS-1597片獲臨床試驗批准

恒瑞醫藥：HRS-6209膠囊、HRS-4508片獲臨床試驗批准

南方财经网

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/IBBQ/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":34.82,"timestamp":1789416000000,"preClose":34.472,"halted":0,"volume":14092,"hourTrading":{"tag":"盘后","latestPrice":34.4,"preClose":34.82,"latestTime":"17:31 EDT","volume":27,"amount":933.299982,"timestamp":1789421478668,"change":-0.42,"changeRate":-0.012062,"amplitude":0.012062},"delay":0,"changeRate":0.01009514968670222,"floatShares":2780001,"shares":2780001,"eps":0,"marketStatus":"盤後交易","change":0.348,"latestTime":"09-14 17:33:12 EDT","open":34.52,"high":34.92,"low":34.42,"amount":489332.36950000003,"amplitude":0.014505,"askPrice":35.14,"askSize":8500,"bidPrice":34.39,"bidSize":8700,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789430400000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":34.472,"sharesOutstanding":2520001,"nav":34.42313,"aum":95742920.24,"dividendRate":0.007412,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":34.4,"preClose":34.82,"latestTime":"17:31 EDT","volume":27,"amount":933.299982,"timestamp":1789421478668,"change":-0.42,"changeRate":-0.012062,"amplitude":0.012062},"volumeRatio":0.801383,"impliedVol":0.1149,"impliedVolPercentile":0.4861},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":2780001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.801383,"shares":2780001,"dividePrice":0.2581,"high":34.92,"amplitude":0.014505,"preClose":34.472,"low":34.42,"week52Low":23.42,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":34.82,"committee":0.011628,"eps":0,"divideRate":0.007412,"volume":14092,"delay":0,"ttmEps":0,"open":34.52,"prevYearClose":28.3962,"prevWeekClose":34.472,"prevMonthClose":35.4742,"prevQuarterClose":32.66,"fiveDayClose":36.05,"twentyDayClose":33.8122,"sixtyDayClose":29.94},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"IBBQ","amount":0.0287,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665257563","title":"製藥巨頭諾華股價大跌近10%，遭遇三項藥物臨床試驗受挫","url":"https://stock-news.laohu8.com/highlight/detail?id=2665257563","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665257563?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 16:50","pubTimestamp":1788857448,"startTime":"0","endTime":"0","summary":"该股最新跌幅达 9.4%。一周之内接连遭遇第三起临床试验挫折，引发投资者抛售，股价或将创下上市以来最差单日交易记录。德尔德西兰临床试验失利数日之前，诺华另一款用于降低心血管事件风险的药物刚在晚期临床试验遇挫；一周前，诺华还宣布，因三名受试者死亡，暂停了实验性细胞疗法 rapcel 的八项临床试验。","market":"us","thumbnail":"http://n.sinaimg.cn/finance/transform/59/w550h309/20260908/d06c-43061a4fc4516fcb77a4d9ff51620de1.png","type":0,"news_type":0,"thumbnails":["http://n.sinaimg.cn/finance/transform/59/w550h309/20260908/d06c-43061a4fc4516fcb77a4d9ff51620de1.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-09-08/doc-inirceww4608579.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["IE0009355771.USD","BK4007","MEDX","BK4532","LU0208291251.USD","IE00BJT1NW94.SGD","BMED","LU0320765489.SGD","IE00B4R5TH58.HKD","IBBQ","PSYK","BK4588","IE00BJJMRZ35.SGD","MDTX","BK4578","IE0002141913.USD","LU0211331839.USD","BK4585","LU0070302665.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","PPH","IBBJ","NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665258833","title":"安進股價盤前下跌5.4%；競爭對手諾華的膽固醇藥物後期臨床試驗失敗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665258833","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665258833?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 16:28","pubTimestamp":1788856084,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","IE00BJJMRZ35.SGD","AMGN","BK4566","LU0109394709.USD","LU1057294990.SGD","PPH","PSYK","LU2468319806.SGD","LU2112291526.USD","BK4581","IE00BJT1NW94.SGD","BIB","PJP","LU0889565916.HKD","IE0002141913.USD","LU0122379950.USD","IE00BFTCPJ56.SGD","LU2242652126.USD","LU0320765992.SGD","BBH","LU0208291251.USD","BK4588","BK4533","BMED","LU1023059063.AUD","LU0058720904.USD","LU0868494617.USD","BK4532","IBBQ","LU2242646821.SGD","LU0289739699.SGD","IBB","LU1983299246.USD","BK4007","IBBJ","NVS","PBE","BK4578","LU1061106388.HKD","LU0320765489.SGD","MDTX","LU0070302665.USD","LU0211331839.USD","BK4534","BK4585","TBXU","SG9999001440.SGD","LU2089984988.USD","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665323037","title":"邁普醫學(301033.SZ)：「可吸收止血流體明膠」進入臨床試驗階段","url":"https://stock-news.laohu8.com/highlight/detail?id=2665323037","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665323037?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 16:21","pubTimestamp":1788855709,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈普医学(301033.SZ)发布公告，公司的研发项目“可吸收止血流体明胶”于近期正式进入临床试验阶段。该医疗器械临床用途：在外科手术中，当压迫、结扎、电凝或其他传统的止血方法无法控制小动脉、静脉及毛细血管的出血，或上述方法无法操作时，可使用可吸收止血流体明胶进行辅助止血。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493299.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","301033","MDTX","PSYK","BK0251","IBBJ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665332349","title":"邁普醫學：可吸收止血流體明膠作為第三類醫療器械進入臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2665332349","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665332349?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 16:14","pubTimestamp":1788855283,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","BMED","HART","LGHT","PTH","IEIH","RSPH","AGNG","MDTX","IBBJ","IBBQ","MDEV","GDOC","LNGR","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665342986","title":"創新藥概念午後拉升，亞太藥業直線漲停，百普塞斯升逾10%，萬邦醫藥、皓元醫藥升逾6%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665342986","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665342986?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 13:44","pubTimestamp":1788846270,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LNGR","MEDX","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665342373","title":"諾華DM1藥物III期臨床試驗未達到主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2665342373","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665342373?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 13:31","pubTimestamp":1788845477,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4532","MDTX","IE00B4R5TH58.HKD","BK4007","LU0070302665.USD","LU0208291251.USD","BK4588","LU0320765489.SGD","IBBJ","IE00BFTCPJ56.SGD","PPH","IE0002141913.USD","IE00BJJMRZ35.SGD","BK4578","NVS","IBBQ","IE00B2B36J28.USD","IE0009355771.USD","LU0211331839.USD","PSYK","IE00BJT1NW94.SGD","BMED","BK4585","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665341826","title":"酶的戰爭：一場或將重塑全球創新藥競爭格局的「皮下革命」","url":"https://stock-news.laohu8.com/highlight/detail?id=2665341826","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665341826?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 11:13","pubTimestamp":1788837196,"startTime":"0","endTime":"0","summary":"算上诺华，已有10家全球制药巨头为ALT-B4签下许可协议。有意思的地方在于：这些交易里没有一款新药。2025年9月，默沙东的Keytruda Qlex获FDA批准，成为首个使用ALT-B4的商业化产品。第一张牌，宝济药业的“国产first”。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1788753577275365008","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1574","IBBQ","MEDX","06978","159992","BK1161","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665349003","title":"富國銀行上調安進目標價至435美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665349003","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665349003?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 11:12","pubTimestamp":1788837128,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["UDN","BK4566","AMGN","UUP","IE00B2B36J28.USD","LU1571399168.USD","LU1061106388.HKD","LU2468319806.SGD","LU0889565916.HKD","BK4139","BK4533","LU1057294990.SGD","BK4582","BIB","IE00B4R5TH58.HKD","LU0109394709.USD","LU1983299246.USD","LU2112291526.USD","BBH","IE00BFTCPJ56.SGD","IBB","PGF","IE0009355771.USD","PBE","LU1023059063.AUD","LU0058720904.USD","PJP","LU2242646821.SGD","BK4585","LU0868494617.USD","BK4534","LU2242652126.USD","BK4581","LU0289739699.SGD","LU2089984988.USD","SG9999001440.SGD","LU0320765992.SGD","IE0002141913.USD","BK4599","IE00BJJMRZ35.SGD","LU0122379950.USD","TBXU","IBBQ","IE00BJT1NW94.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665311078","title":"上半年創新藥冰火兩重天：百濟神州一款藥賣了超160億元，六成藥企還在求生","url":"https://stock-news.laohu8.com/highlight/detail?id=2665311078","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665311078?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 20:39","pubTimestamp":1788784781,"startTime":"0","endTime":"0","summary":"2026年上半年财报季收官，中国创新药产业交出了一份分水岭式的答卷。行业正在告别“烧钱讲故事”的阶段，走向“赚钱才是硬道理”的价值兑现期。这种转变并非行业普遍现象，而是由商业化放量、出海授权爆发、资金来源多元化三重力量共同推动的分化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609073866904351.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609073866904351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ONC","LU0307460666.USD","LU1303224171.USD","LU1719994722.HKD","LU0228659784.USD","688235","MEDX","LU0588546209.SGD","BK4585","BK1500","LU1969619763.USD","LNGR","LU1251922891.USD","BK4526","LU0828237510.HKD","LU2328871848.SGD","BK1161","BK1583","BK4588","06160","IBBQ","LU1770034418.SGD","KURE","06978","BK1588","159992","BK4139","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319978","title":"石藥集團(01093)：SYH2085片用於治療成人單純性流感的II期臨床試驗在中國正式啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319978","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665319978?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 19:30","pubTimestamp":1788780616,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团开发的SYH2085片用于治疗成人无并发症的单纯性流行性感冒的II期临床试验已于中国首家中心正式启动。此前，集团已于2025年12月获中国国家药品监督管理局就该产品签发的《药物临床试验批准通知书》。本次启动的该产品临床试验为多中心、随机、双盲、安慰剂对照的II期临床研究，旨在评价该产品治疗中国成人无并发症的单纯性流行性感冒参与者中的有效性及安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492970.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0326950275.SGD","IE00BZ08YS42.EUR","LU1226287875.USD","LU0314109678.HKD","01093","IE0008368742.USD","BK1191","LU1226287792.SGD","LU1807302812.USD","IBBJ","LU1951186391.HKD","SG9999004220.SGD","IE0008369823.USD","KURE","LU1813983027.USD","IE00B031HY20.USD","LU1226288170.HKD","IE00BZ08YT58.USD","LU1993786604.SGD","IBBQ","PSYK","LU1152091754.HKD","HK0000165453.HKD","LU2039709279.SGD","LU0140636845.USD","LU1226287529.USD","BK1521","LU1960683339.HKD","MDTX","LU0067412154.USD","LU0315179316.USD","IE00B543WZ88.USD","LU0880133367.SGD","LU1226288253.USD","BMED","LU1152091168.USD","LU0072913022.USD","IE00B5MMRT66.SGD","LU0501845795.SGD","LU1328277881.USD","BK1515","LU1008478684.HKD","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319936","title":"石藥集團：SYH2085片II期臨床試驗在中國正式啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319936","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665319936?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 19:28","pubTimestamp":1788780492,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","PSYK","BMED","IBBQ","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665831989","title":"繼諾華之後，諾和諾德(NVO.US)終止兩項心血管臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2665831989","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665831989?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 19:10","pubTimestamp":1788779458,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BJJMRZ35.SGD","BK4585","BK4532","PPH","IE00B4R5TH58.HKD","PSYK","LU0211331839.USD","IE0009355771.USD","LU0070302665.USD","LU0320765489.SGD","IE00BFTCPJ56.SGD","NVS","BK4578","IE00BJT1NW94.SGD","BMED","IE0002141913.USD","LU0208291251.USD","MDTX","IBBQ","BK4588","BGIA","IE00B2B36J28.USD","BK4007","IBBJ","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665031616","title":"恒瑞醫藥(01276)：SHR-1179注射液獲得藥物臨床試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2665031616","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665031616?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 18:49","pubTimestamp":1788778166,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，近日，江苏恒瑞医药股份有限公司(以下简称“公司”)子公司广东恒瑞医药有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于 SHR-1179 注射液的《药物临床试验批准通知书》，将于近期开展临床试验。SHR-1179 注射液是公司自主研发的治疗用 1 类生物制品，拟用于体重管理适应症，国内外暂无相同靶点药物获批上市。截至目前，SHR-1179 注射液相关项目累计研发投入约2,420万元(未经审计)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492927.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2148510915.USD","LU2495084118.USD","LU0359201612.USD","IBBQ","BK0012","LU2097828631.EUR","MDTX","LU0405327494.USD","LU2580892789.USD","LU2543165471.USD","LU1969619763.USD","LU2097828557.USD","LU0359202008.SGD","LU2488822045.USD","IBBJ","BMED","LU1064131003.USD","LU0405327148.USD","600276","BK0028","BK0239","PSYK","BK0196","LU2097828714.EUR","LU2097828805.USD","LU1064130708.USD","LU2580892862.HKD","LU2328871848.SGD","BK1191","LU1781817850.SGD","LU1255011170.USD","LU1997245094.SGD","LU0359201885.HKD","LU1820825898.SGD","LU1580142542.USD","LU1146622755.USD","BK0060","LU1655091616.SGD","LU2097828474.EUR","LU2289578879.USD","BK0183","LU1997245177.USD","LU1328615791.USD","LU1023057109.AUD","LU1997244956.HKD","BK0188","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665731933","title":"榮昌生物：關於參加科創板2026年半年度創新藥行業集體業績説明會的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2665731933","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665731933?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 18:43","pubTimestamp":1788777780,"startTime":"0","endTime":"0","summary":"证券日报网讯9月7日，荣昌生物发布公告称，公司计划于2026年9月16日15：00-17：00参加2026年半年度科创板创新药行业集体业绩说明会，就投资者关心的问题进行交流。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-07/doc-iniqyzxs9619866.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-07/doc-iniqyzxs9619866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LNGR","LU1064131003.USD","BK0239","BK1583","IBBQ","BK1161","LU2148510915.USD","LU1969619763.USD","BK1574","159992","KSTR","LU2328871848.SGD","06978","LU1064130708.USD","688331","09995","MEDX","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665315689","title":"諾和諾德再次暫停了其實驗性心臟病藥物的兩項臨床試驗，進一步打擊了該藥的發展前景。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665315689","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665315689?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 18:02","pubTimestamp":1788775332,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA","MDTX","PSYK","BMED","IBBQ","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319730","title":"艾迪藥業：關於參加科創板2026年半年度創新藥行業集體業績説明會的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319730","media":"证券日报网","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665319730?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 18:01","pubTimestamp":1788775260,"startTime":"0","endTime":"0","summary":"证券日报网讯9月7日，艾迪药业发布公告称，公司计划于2026年9月16日15：00-17：00参与由上海证券交易所主办的科创板2026年半年度创新药行业集体业绩说明会。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-07/doc-iniqyzxw5472550.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-07/doc-iniqyzxw5472550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBBQ","KSTR","LNGR","MEDX","159992","BK1161","BK1574","06978","688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665313519","title":"恒瑞醫藥(600276.SH)子公司HRS-1597片獲批開展臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2665313519","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665313519?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 17:18","pubTimestamp":1788772689,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司山东盛迪医药有限公司收到国家药品监督管理局核准签发关于HRS-1597片的《药物临床试验批准通知书》，将于近期开展临床试验。HRS-1597片是公司自主研发的1类新药，拟用于体重管理。经查询，目前国内外暂无同类药物获批上市。截至目前，HRS-1597片相关项目累计研发投入约1690万元(未经审计)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492818.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","LU1023057109.AUD","LU1255011170.USD","LU1997245094.SGD","LU0359201885.HKD","LU2580892789.USD","BK0196","LU2495084118.USD","BK0012","LU0405327494.USD","BK0183","LU2289578879.USD","LU1969619763.USD","BK0060","BK0188","LU2488822045.USD","BMED","600276","LU1997244956.HKD","LU1064131003.USD","LU2097828631.EUR","LU1146622755.USD","LU2097828557.USD","LU0405327148.USD","LU2148510915.USD","LU1655091616.SGD","LU1328615791.USD","LU2328871848.SGD","LU1820825898.SGD","IBBQ","LU2580892862.HKD","LU1997245177.USD","BK1191","LU2543165471.USD","LU2097828474.EUR","MDTX","LU1064130708.USD","LU2097828805.USD","LU0359202008.SGD","LU1580142542.USD","LU2097828714.EUR","LU0359201612.USD","LU1781817850.SGD","BK0239","PSYK","01276","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665313385","title":"智飛生物(300122.SZ)：重組輪狀病毒亞單位疫苗(大腸桿菌)獲得臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665313385","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665313385?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 17:15","pubTimestamp":1788772542,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物 发布公告，公司于近日获悉，由全资子公司北京智飞绿竹生物制药有限公司研发的重组轮状病毒亚单位疫苗获得国家药品监督管理局药物临床试验批准通知书，同意开展预防轮状病毒感染引起的急性胃肠炎的临床试验。公司的重组轮状病毒亚单位疫苗采用重组大肠杆菌发酵、纯化等工艺，获得三种基因型的重组VP8蛋白，经佐剂吸附制备成疫苗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492816.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBJ","LU1328615791.USD","LU2580892789.USD","300122","LU1064131003.USD","IBBQ","BK0188","BK0077","BK0196","159646","LU2148510915.USD","BK0239","BK0046","BMED","LU2580892862.HKD","PSYK","LU1064130708.USD","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665831854","title":"恒瑞醫藥：子公司HRS-1597片獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665831854","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665831854?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 16:47","pubTimestamp":1788770825,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BMED","IBBQ","PSYK","IBBJ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665181063","title":"恒瑞醫藥：HRS-6209膠囊、HRS-4508片獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665181063","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665181063?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 16:47","pubTimestamp":1788770820,"startTime":"0","endTime":"0","summary":"南财智讯9月7日电，恒瑞医药公告，HRS-6209胶囊、HRS-4508片收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意开展临床试验。通知书明确：HRS-6209联合其他抗肿瘤治疗在晚期不可切除或转移性乳腺癌，或HRS-9813在晚期实体瘤患者中的安全性、耐受性、药代动力学及初步疗效的开放、多中心Ib/II期临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609073866721614.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609073866721614.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBBJ","LU2543165471.USD","LU0359202008.SGD","LU1064131003.USD","LU2488822045.USD","LU0359201885.HKD","LU2097828805.USD","BMED","LU2097828714.EUR","LU2580892862.HKD","LU1781817850.SGD","LU1064130708.USD","BK0196","LU1997245094.SGD","BK0012","BK0183","01276","LU1820825898.SGD","LU1023057109.AUD","BK0239","LU1655091616.SGD","LU2289578879.USD","LU2328871848.SGD","LU1997245177.USD","LU2097828474.EUR","PSYK","BK0060","BK0188","BK1191","LU1146622755.USD","LU2097828557.USD","LU2580892789.USD","IBBQ","LU2495084118.USD","LU1997244956.HKD","LU1969619763.USD","LU0405327494.USD","LU2097828631.EUR","600276","LU2148510915.USD","LU1255011170.USD","LU1328615791.USD","LU1580142542.USD","LU0359201612.USD","MDTX","BK0028","LU0405327148.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":6,"totalSize":201,"code":"91000000","status":"200"}]}}